CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for BioAge Labs, Inc. (BIOA)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for BIOA, mapped to public ticker BIOA (CIK 0001709941). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingBIOA55% conf

BioAge Labs, Inc. (BIOA) — PHASE2 primary completion in ~162 days

Upstream (observed)
Clinical trial status (PHASE2) — A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →